MAHLY (Medipal Holdings) Cyclically Adjusted Revenue per Share: $135.91 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAHLY Medipal Holdings Corp MAHLY
69 GF Score
Price $20.21
GF Value $16.53
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medipal Holdings Cyclically Adjusted Revenue per Share?

Medipal Holdings MAHLY +6.90% 69 Cyclically Adjusted Revenue per Share is $135.91 as of Mar. 2026. GuruFocus rates MAHLY with a GF Score™ of 69/100 and a GF Value™ of $16.53 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medipal Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was $28.200. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $135.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medipal Holdings's average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medipal Holdings was 5.00% per year. The lowest was 2.20% per year. And the median was 3.55% per year.

As of today (2026-09-17), Medipal Holdings's current stock price is $20.21. Medipal Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $135.91. Medipal Holdings's Cyclically Adjusted PS Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medipal Holdings was 0.21. The lowest was 0.11. And the median was 0.16.


Medipal Holdings  (OTCPK:MAHLY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medipal Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=20.21/135.91
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medipal Holdings was 0.21. The lowest was 0.11. And the median was 0.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medipal Holdings Cyclically Adjusted Revenue per Share Related Terms


Medipal Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medipal Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medipal Holdings Cyclically Adjusted Revenue per Share Chart

Medipal Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.89 130.06 130.63 133.86 135.27

Medipal Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.23 135.66 136.70 135.91 136.38

MAHLY vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Medipal Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipal Holdings Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's Cyclically Adjusted PS Ratio falls into.


MAHLY
69GF Score
Medipal Holdings Corp MAHLY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medipal Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medipal Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=28.2/112.7000*112.7000
=28.200

Current CPI (Mar. 2026) = 112.7000.

Medipal Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 31.539 98.100 36.233
201609 32.736 98.000 37.646
201612 32.266 98.400 36.955
201703 28.557 98.100 32.807
201706 31.008 98.500 35.478
201709 31.039 98.800 35.406
201712 31.325 99.400 35.516
201803 29.077 99.200 33.034
201806 30.982 99.200 35.198
201809 29.740 99.900 33.551
201812 31.577 99.700 35.694
201903 29.288 99.700 33.107
201906 31.319 99.800 35.367
201909 33.514 100.100 37.733
201912 33.847 100.500 37.956
202003 31.540 100.300 35.439
202006 33.106 99.900 37.348
202009 33.542 99.900 37.840
202012 37.124 99.300 42.134
202103 32.634 99.900 36.815
202106 33.784 99.500 38.266
202109 33.314 100.100 37.507
202112 34.051 100.100 38.337
202203 30.196 101.100 33.661
202206 28.983 101.800 32.086
202209 27.562 103.100 30.128
202212 29.296 104.100 31.716
202303 28.512 104.400 30.779
202306 30.182 105.200 32.334
202309 29.050 106.200 30.828
202312 29.960 106.800 31.615
202403 27.060 107.200 28.448
202406 27.836 108.200 28.994
202409 29.413 108.900 30.439
202412 31.006 110.700 31.566
202503 27.267 111.100 27.660
202506 31.488 111.700 31.770
202509 31.324 112.000 31.520
202512 32.075 113.000 31.990
202603 28.200 112.700 28.200

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $135.91 mean?
Medipal Holdings (MAHLY) has a Cyclically Adjusted Revenue per Share of $135.91 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medipal Holdings and its competitors.
Is Medipal Holdings' Cyclically Adjusted Revenue per Share too high?
Medipal Holdings' current Cyclically Adjusted Revenue per Share is $135.91. Overall, Medipal Holdings has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Cyclically Adjusted Revenue per Share compare to MCK and COR?
Medipal Holdings' Cyclically Adjusted Revenue per Share of $135.91 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medipal Holdings and its competitors. Medipal Holdings's current Cyclically Adjusted Revenue per Share is $135.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.53, compared to a current price of $20.21 — trading 22.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $135.91. Medipal Holdings' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current Cyclically Adjusted Revenue per Share is $135.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MAHLY) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued. The current stock price of $20.21 is trading 22.3% above its estimated GF Value™ of $16.53. GuruFocus considers Medipal Holdings to be Modestly Overvalued.

Key valuation signals for MAHLY:

  • Cyclically Adjusted Revenue per Share: $135.91
  • GF Value™: $16.53 vs. price of $20.21 (22.3% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medipal Holdings Business Description

Other Exchanges MEPDF:USA7459:Japan
Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
69GF Score

Get the complete analysis for MAHLY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.21
Price
$16.53
GF Value